Search

Displaying results 4531 - 4540 of 7452 in total
  1. Drug

    HH-009

    go.drugbank.com/drugs/DB18727
    Investigational

    HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.

  2. Drug

    TBI-223

    go.drugbank.com/drugs/DB18911
    Investigational

    TBI-223 is under investigation in clinical trial NCT06192160 (Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis).

  3. Drug

    Ginsenoside Rd

    go.drugbank.com/drugs/DB19256
    Investigational

    Ginsenoside Rd is under investigation in clinical trial NCT00815763 (Efficacy and Safety of Ginsenoside-rd for Acute Ischemic Stroke).

  4. Drug

    Ovatodiolide

    go.drugbank.com/drugs/DB19264
    Investigational

    Ovatodiolide is under investigation in clinical trial NCT04220411 (A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)).

  5. Drug

    Artemisone

    go.drugbank.com/drugs/DB16097
    Investigational

    Artemisone is under investigation in clinical trial NCT00936767 (Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia).

  6. Drug

    Sarpogrelate

    go.drugbank.com/drugs/DB12163
    Investigational

    Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.

  7. Drug

    Rovadicitinib

    go.drugbank.com/drugs/DB21747
    Investigational

    Rovadicitinib is under investigation in clinical trials NCT06682169 and NCT06300320 for the treatment of Chronic Graft-versus-host Disease.

  8. Drug

    Carbarsone

    go.drugbank.com/drugs/DB11382
    ExperimentalVet approved

    Carbarsone is a compound used as an antiprotozoal drug for the treatment of histomoniasis (or blackhead disease) in addition to other infectious diseases in chicken and turkeys.

  9. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

  10. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2.